LWBK1006-10 LWW-Govindan-Review November 24, 2011 11:21
Chapter 10•Health Services Research and Economics of Cancer Care 117Question 10.8. Which of the following is TRUE regarding measurement of health-related
quality of life (HRQOL)?
A. Efforts should be made to use the same instrument across studies to
allow comparisons.
B. Validated HRQOL instruments are both precise and accurate.
C. HRQOL instruments are easily translated into different languages.
D. Computerized adaptive testing allows more precise measurement of
HRQOL, while reducing the number of questions asked.Question 10.9. The burden of symptoms on a patient can be quantified by measures
of “utility.” Which of the following is TRUE regarding “utility” in this
sense?
A. It measures the impact of disease on a patient’s independence.
B. It numerically compares how a patient would value living with a
specific disease state in comparison to perfect health.
C. It measures the burden of relieving the symptoms on the health care
system.
D. It specifically refers to a patient’s evaluation of his/her own disease.Question 10.10. Which of the following is NOT true regarding the costs of health care in
the United States?
A. Total annual health care expenditures are approximately $2 trillion,
or $7000 per person.
B. Approximately 30% of health care expenses occur in the last year of
life.
C. The costs associated with cancer care are estimated to be 15% of
overall medical expenses and 30% of Medicare expenses.
D. Cancer pharmaceuticals account for 40% of all Medicare pharma-
ceutical spending.Question 10.11. Which of the following is TRUE regarding comparative effectiveness
research (CER) in cancer care?
A. By definition, CER evaluates outcome differences in “real-world”
settings.
B. CER will be performed primarily through meta-analysis of existing
clinical trials.
C. CER is intended primarily to compare costs between two treatments.
D. CER is not performed on prospectively collected data.